Pancreatitis

Common

Ankle swelling Common

Rash

suspected, gallbladder studies are indicated.

Liver and biliary system disorders Rare cholestatic jaundice, disturbed liver function, hepatitis, cholelithiasis, cholecystitis.

Metabolism Degarelix is subject to common peptidic degradation during the passage of the hepato biliary system and is mainly excreted as peptide fragments in the faeces.

The doctor diagnosed it as a gallstone.

Gall bladder disease Gall bladder disease has been reported after treatment with oestrogen progestagen.

Hypersensitivity to the active substances, to any of the excipients (see section 6.1), or to other sulfonamide derived substances (hydrochlorothiazide is a sulfonamide derived substance) Second and third trimester of pregnancy (see sections 4.4 and 4.6) Lactation (see section 4.6) Severe renal impairment (creatinine clearance 30 ml min) Refractory hypokalaemia, hypercalcaemia Severe hepatic impairment, biliary cirrhosis and cholestasis

Severe renal impairment (creatinine clearance 30 ml min), Refractory hypokalaemia, hypercalcaemia, Severe hepatic impairment, biliary cirrhosis and cholestasis.

Severe hepatic impairment, biliary cirrhosis and cholestasis.

Inflammation of the gallbladder.

Transaminases increased Hepatitis, cholelithiasis Hepatic failure 1 P P

hepatic necrosis, hepatitis, hepatic steatosis, cholelithiasis, blood bilirubin increased

The biliary hyperplasia regressed upon cessation of dosing.

The biliary hyperplasia regressed upon cessation of dosing.

So this is gallbladder surgery.

However, hepatic disease with predominantly biliary damage, such as primary biliary cirrhosis, may show a different effect.

Severe hepatic impairment, biliary cirrhosis or cholestasis.

Blood cholesterol abnormal, Blood glucose abnormal, Blood glucose decreased, Low density lipoprotein increased

Biliary fibrosis has been observed in rats.

Erlotinib is eliminated by hepatic metabolism and biliary excretion.

Biliary excretion may also contribute to the elimination.

1 of the dose is excreted via the biliary route.

liver inflammation (hepatitis), destruction of liver tissue (liver cell necrosis, very rarely resulting in life threatening liver failure)

His gall bladder spent a rather peaceful night.

The biliary hyperplasia regressed upon cessation of dosing.

Erlotinib is eliminated by hepatic metabolism and biliary excretion.

Rare Body as a whole fatigue, fever, malaise, influenza like symptoms Central and peripheral nervous system dizziness, headache, paresthesia Gastro intestinal system nausea, vomiting, diarrhoea, abdominal pain Liver and biliary system abnormal liver function tests Musculoskeletal system arthralgia, myalgia Skin and appendages rash, pruritus, urticaria

Irbesartan and its metabolites are eliminated by both biliary and renal pathways.

Rare Body as a whole fatigue, fever, malaise, influenza like symptoms Central and peripheral nervous system dizziness, headache, paresthesia Gastro intestinal system nausea, vomiting, diarrhoea, abdominal pain Liver and biliary system abnormal liver function tests Musculoskeletal system arthralgia, myalgia Skin and appendages rash, pruritus, urticaria

P glycoprotein interactions MDR1 Mdr1a 1b (P gp) was found to be the major efflux system involved in intestinal absorption and biliary excretion of aliskiren in preclinical studies.

MDR1 Mdr1a 1b (P gp) was found to be the major efflux system involved in intestinal absorption and biliary excretion of aliskiren in preclinical studies.

On the other hand, more than 95 percent of manganese is eliminated by biliary excretion.

Only dic

Orlistat, M1 and M3 are all subject to biliary excretion.

Both biliary and urinary excretion contribute to the elimination of losartan and its metabolites.

Kinzalkomb should not be given to patients with cholestasis, biliary obstructive disorders or severe hepatic insufficiency (see section 4.3) since telmisartan is mostly eliminated with the bile.

Kinzalmono is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile.

Micardis is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile.

MicardisPlus should not be given to patients with cholestasis, biliary obstructive disorders or severe hepatic insufficiency (see section 4.3) since telmisartan is mostly eliminated with the bile.

Pritor is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile.

PritorPlus should not be given to patients with cholestasis, biliary obstructive disorders or severe hepatic insufficiency (see section 4.3) since telmisartan is mostly eliminated with the bile.

However, there was no association between the occurrence of adverse events related to the biliary system in darifenacin treated patients and increasing age.